This article looks at the 14 Best Multibagger Penny Stocks to Buy Right Now.The Russell 2000 Index has hit fresh highs heading into 2026, signaling renewed interest in small companies. The index is already up by more than 13% for the year as market rotation from large-cap stocks gathers pace.The renewed focus on penny and small-cap stocks comes as investors rotate into higher-risk, higher-reward assets. The shift also underscores growing confidence in the broader economy and corporate sector, as they are ex ...

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh. ...

Core Viewpoint - ADC Therapeutics SA has announced updated results from the LOTIS-7 clinical trial, highlighting the potential of ZYNLONTA in treating DLBCL (Diffuse Large B-cell Lymphoma) [2][3]. Group 1: Clinical Trial Update - The LOTIS-7 clinical trial results were shared in a press release and are available on the company's website [2]. - The Chief Medical Officer, Mohamed Zaki, will provide detailed insights into the LOTIS-7 clinical trial and its updated results during the call [3]. Group 2: Strategic Overview - Ameet Mallik, the Chief Executive Officer, will present a strategic overview and discuss the opportunity for ZYNLONTA in the DLBCL market [3].

LOTIS-7 Clinical Trial Results and Strategy - The LOTIS-7 trial (ZYNLONTA + glofitamab) showed an overall response rate (ORR) of 89.8% (44/49 patients) in 2L+ LBCL patients[37] - The complete response (CR) rate in the LOTIS-7 trial was 77.6% (38/49 patients)[41] - In the LOTIS-7 trial, 6 out of 8 patients previously treated with CAR-T achieved a CR[41] - Grade 3 or higher treatment emergent adverse events (TEAEs) occurred in >5% of patients, including neutropenia (32.7%), GGT increased (16.3%), and anemia (10.2%)[40] - Grade 5 AEs occurred in 4.1% (2/49) of patients in the LOTIS-7 trial[40] - Cytokine release syndrome (CRS) of any grade was observed in 36.7% (18/49) of patients in the LOTIS-7 trial[47] Market Opportunity and Revenue Potential - ZYNLONTA has a U S peak revenue potential of $600 million to $1 billion in DLBCL and indolent lymphomas[56] - The company believes LOTIS-7 has the potential to be the leading bispecific combination regimen for patients with access to complex therapies[17] - The company believes LOTIS-5 has the potential to be the leading regimen for patients who will not receive complex therapies[17] Upcoming Milestones - The company expects full enrollment of 100 patients at selected dose for LOTIS-7 in 1H2026[59] - The company expects to share topline results for LOTIS-5[59]

3Q 2025 Earnings Call November 10, 2025 Agenda 01 Introduction Ameet Mallik Chief Executive Officer 03 Chief Financial Officer Financial Update Pepe Carmona 04 Q&A 2 Forward-Looking Statements 02 Clinical Highlights Mohamed Zaki Chief Medical Officer This presentation and any accompanying oral presentation have been prepared by ADC Therapeutics SA ("ADC Therapeutics", "we" or "us") for informational purposes only and not for any other purpose. Nothing contained in this presentation is, or should be construe ...

Group 1 - ADC Therapeutics (ADCT) is a biotech firm focused on developing Antibody Drug Conjugates (ADCs) for cancer therapy, utilizing proprietary PBD technology to enhance treatment efficacy while minimizing damage to healthy tissue [4] - On October 16, H.C. Wainwright reaffirmed its Buy rating on ADC Therapeutics but lowered the price target from $8 to $7 following the company's announcement of a $60 million PIPE financing deal [1][2] - The PIPE financing involves the sale of 11.3 million common shares at $4.00 each and pre-funded warrants for 3.8 million shares at $3.90 each, with net proceeds expected to total approximately $57.6 million after fees and expenses [2] Group 2 - The financing strengthens ADC Therapeutics' balance sheet, increasing its pro forma cash position to an estimated $292.3 million [3] - The company anticipates reporting $15.8 million in net product revenue from ZYNLONTA sales for Q3 2025, with $234.7 million in cash and equivalents as of September 30 [3]

Group 1 - ADC Therapeutics (ADCT) is recognized as a promising long-term penny stock with significant upside potential [1] - H.C. Wainwright analyst Robert Burns has lowered the price target for ADC Therapeutics from $8 to $7 while maintaining a Buy rating [1][2] - The price target adjustment follows a $60 million private placement financing announced on October 12, which is expected to close on October 27 [2] Group 2 - The proceeds from the private placement will support the commercial expansion of ZYNLONTA, a treatment for adults with relapsed B-cell lymphoma [2] - The financing is also aimed at strengthening the company's balance sheet and positioning it for long-term growth, with potential plans for a ZYNLONTA relaunch in 2027 [2] - ADC Therapeutics specializes in antibody drug conjugate technology, focusing on transforming treatment paradigms for patients with hematologic malignancies and solid tumors [3]

Core Viewpoint - ADC Therapeutics has announced a $60 million private investment in public equity (PIPE) financing to support the commercial expansion of its product ZYNLONTA and strengthen its balance sheet [1][3][4]. Financing Details - The PIPE involves the sale of 11.3 million common shares at $4.00 per share and pre-funded warrants for 3.8 million common shares at $3.90 each [1][2]. - Gross proceeds from the PIPE are expected to be approximately $60 million before fees and expenses, with the closing anticipated on October 27, 2025 [3]. Use of Proceeds - The net proceeds from the PIPE will be utilized for the commercial expansion of ZYNLONTA, strengthening the balance sheet, funding working capital, and general corporate purposes [3][4]. Financial Expectations - The company projects net product revenues from ZYNLONTA sales to be around $15.8 million for Q3 2025, with cash and cash equivalents totaling $234.7 million as of September 30, 2025 [4]. - After accounting for estimated net proceeds from the PIPE, the company expects to have approximately $292.3 million in cash and cash equivalents [4]. Product Information - ZYNLONTA is a CD19-directed antibody drug conjugate approved for treating adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy [9][13]. - The drug is also being evaluated in combination studies for other B-cell malignancies and earlier lines of therapy [11][13].

Summary of ADC Therapeutics Conference Call Company Overview - **Company**: ADC Therapeutics - **Industry**: Biotechnology, specifically focused on antibody-drug conjugates (ADCs) - **Lead Product**: ZYNLONTA (anti-CD19 ADC) approved for third-line treatment of diffuse large B-cell lymphoma (DLBCL) as a monotherapy [2][3] Core Points and Arguments - **Market Opportunity**: ADC Therapeutics estimates a peak sales opportunity for ZYNLONTA between $600 million to $1 billion, driven by ongoing clinical trials and a favorable competitive landscape [4][3] - **Clinical Trials**: - LOTIS-5: Phase 3 study combining ZYNLONTA with rituximab in second-line DLBCL, with data expected by the end of the year [5][15] - LOTIS-7: Phase 2 study combining ZYNLONTA with Roche's glofitamab, showing promising early results with a 93% overall response rate and 87% complete response rate in initial patients [25][27] - **Competitive Landscape**: The company believes that the DLBCL market is less competitive than perceived, with only 20% of patients receiving CAR-T therapy due to accessibility issues, leaving a significant opportunity for ZYNLONTA [7][9] Important Data Points - **LOTIS-5 Expectations**: Aiming for a progression-free survival (PFS) benefit of approximately 6 months over the current standard of care, with a complete response (CR) rate target of 40-50% [16][19] - **LOTIS-7 Results**: The combination therapy has shown a favorable safety profile with no new safety signals and a lower incidence of neutropenia compared to historical data [28][30] - **Indolent Lymphomas**: Ongoing studies in high-grade follicular and marginal zone lymphoma show promising early results, with a 97% overall response rate and 77% complete response rate in follicular lymphoma [42][43] Financial Position - **Cash Position**: ADC Therapeutics ended Q2 with $265 million in cash, providing a runway into 2028 [54] - **Upcoming Catalysts**: Expected revenue opportunities from potential approvals and guideline inclusions for LOTIS-5 and LOTIS-7 by the first half of 2027 [54] Additional Insights - **Regulatory Engagement**: The company is actively engaging with the FDA and plans to submit data for LOTIS-5, aiming for a swift transition from data readout to submission [24][36] - **Partnership with Roche**: Roche is a key partner in the LOTIS-7 study, providing clinical drug supply and regulatory insights [37][38] - **Market Dynamics**: The company highlights that the DLBCL market is evolving, with a significant portion of patients still lacking effective treatment options, positioning ZYNLONTA as a potential new standard of care [10][12] This summary encapsulates the key points discussed during the conference call, focusing on ADC Therapeutics' strategic direction, clinical trial progress, market opportunities, and financial health.

Commercial Performance - 2Q 2025 net product revenues reached $18.1 million, a 6.2% increase compared to $17.0 million in the same quarter of 2024 [16, 58] - Total 1H 2025 net product revenue was $35.5 million, up from $34.9 million during the 1H of 2024 [16] Pipeline Progress - LOTIS-7 data showed a 93.3% ORR (Overall Response Rate) and an 86.7% CR (Complete Response) rate across 30 efficacy evaluable patients when ZYNLONTA was combined with glofitamab [16, 53] - Updated MZL IIT data presented at ICML demonstrate an 85% ORR and a 69% CR rate [16] - LOTIS-5 is on track to reach pre-specified PFS (Progression-Free Survival) events by the end of 2025 [16] Corporate Update - The company secured $100 million in private placement, extending the expected cash runway into 2028 [16] - A strategic prioritization was implemented, resulting in a 30% reduction in force and one-time charges of $13.1 million, including $6.7 million in employee severance and $6.4 million in non-cash impairment of assets related to the UK facility closure [16] - The company's cash balance was $264.6 million as of June 30, 2025 [16, 58] LOTIS-7 Trial Safety - In the LOTIS-7 Phase 1b trial, 56.1% of patients experienced Grade 3/4 TEAEs (Treatment-Emergent Adverse Events) [47] - Cytokine Release Syndrome (CRS) of any grade was observed in 39% of patients [49] - ICANS (Immune effector Cell-Associated Neurotoxicity Syndrome) of any grade was observed in 7.3% of patients [49] ZYNLONTA Market Potential - ZYNLONTA has a U S peak revenue potential of $600 million to $1 billion in DLBCL (Diffuse Large B-Cell Lymphoma) and indolent lymphomas [21, 22]